SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GlycoBiology

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates4/13/2005 9:38:15 AM
  Read Replies (1) of 26
 
GlycoFi Signs Research Collaboration with Centocor, Inc. to Evaluate the Expression of Two Proteins
Wednesday April 13, 7:25 am ET

LEBANON, N.H.--(BUSINESS WIRE)--April 13, 2005--GlycoFi announced today that they initiated a collaboration with Centocor, Inc, to determine the feasibility of producing a Centocor protein using GlycoFi's proprietary yeast-based glycoprotein production technology. Under the agreement, Centocor has the option to use the GlycoFi-yeast based production system for future protein expression in return for milestone payments and royalties to GlycoFi. Financial details were not disclosed. In an on-going research study funded by Centocor, GlycoFi and Centocor are also evaluating the use of GlycoFi technology for the production of an undisclosed Centocor antibody. These two collaborations combine GlycoFi's unique expression technology for the production of human glycoproteins, including antibodies, with Centocor's expertise in the area of therapeutic proteins.

About GlycoFi's Technology

Sugars, or glycosylation, on the surface of a protein are known to influence critical pharmaceutical properties of therapeutic proteins and monoclonal antibodies. GlycoFi is the leader in the area of glycosylation engineering in living systems, and its patented, scaleable technology uniquely allows its partners to create specific human glycosylation variants of any therapeutic glycoprotein. For the first time, GlycoFi and its partners can systematically research the impact of a protein's glycovariants on its pharmaceutical properties, enabling the optimization of biological activity, receptor binding, serum half-life, and potency of the drug candidate, thereby reducing the overall development risk of the project.

About GlycoFi

GlycoFi, Inc. is a biotechnology company that leverages its pioneering protein production technology to develop, produce and commercialize Next Generation Biotherapeutics(TM), alone and in partnership with other leading biopharmaceutical companies. For more information, please visit www.glycofi.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext